{"database":"iProX","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["XuefanYu"],"species":["Homo Sapiens"],"full_dataset_link":["http://www.iprox.org/page/project.html?id=IPX0016967000"],"submitter_email":["xuefan@jlu.edu.cn"],"submitter_affiliation":["The First Affiliated Hospital of Jilin University"],"sample_protocol":[""],"repository":["iProX"],"data_protocol":[""],"additional_accession":[]},"is_claimable":false,"name":"Novel phenotypes of immune-mediated necrotizing myopathy identified independent of myositis-specific antibody specificity that improve prognostic stratification","description":"Immune-mediated necrotizing myopathy (IMNM) is a severe autoimmune myopathy with high clinical heterogeneity. Current classification relies on myositis-specific antibodies (MSA: anti-HMGCR, anti-SRP) but fails to explain differences in manifestations, interstitial lung disease (ILD) incidence, and survival. We enrolled 133 IMNM patients, used unsupervised machine learning (MSA-independent) to identify three phenotypes: Phenotype 1 (56.4%, muscle weakness, favorable prognosis), Phenotype 2 (10.5%, high muscle damage indicators, intermediate prognosis), Phenotype 3 (33.1%, high ILD/mortality, poor prognosis). Label-free DIA quantitative proteomics on these phenotypes and noninflammatory controls revealed distinct protein expression patterns, providing molecular evidence for IMNM subtyping, mechanism exploration, and prognosis evaluation.","dates":{"publication":"Wed May 06 00:00:00 BST 2026"},"accession":"PXD078154","cross_references":{"TAXONOMY":["9606"]}}